Strives to address unmet need in the treatments of gout and chronic kidney diseases
Location: United States
Employees: 11-50
Total raised: $228M
Investors 1
| Date | Name | Website |
| - | Heda Ventu... | hedaventur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.10.2025 | Series E | $153M | Highlight ... |
| 12.07.2023 | Series D | $75M | - |
Mentions in press and media 18
| Date | Title | Description |
| 21.05.2026 | Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout | Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout Thu, May 21, 2026 22:30 CET Report this content Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at m... |
| 15.10.2025 | Arthrosi Secures $153 Million to Accelerate Gout Treatment | Arthrosi Therapeutics recently closed a significant $153 million Series E funding round. This vital capital directly supports late-stage clinical development of pozdeutinurad, a promising next-generation URAT1 inhibitor. The San Diego-based... |
| 14.10.2025 | Arthrosi: $153 Million Series E Raised For Developing Gout Treatments | Arthrosi Therapeutics has closed a $153 million Series E funding round. This late-stage biotechnology company is focused on developing a next-generation URAT1 inhibitor, which has the potential to be a best-in-class treatment for patients s... |
| 08.10.2025 | Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026 | Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year. San Diego-based Arthrosi completed enrollme... |
| 08.10.2025 | Arthrosi Raises $153M in Series E Funding | Arthrosi, a San Diego, CA-based late-stage biotechnology company developing URAT1 inhibitors, raised $153M in Series E funding. The round was led by Prime Eight Capital Limited and with participation from CR Biotech, HighLight Capital, HM V... |
| 03.09.2024 | The Rise of Private Credit: SeaTown's Bold Move in Asia | In the ever-evolving landscape of finance, private credit is emerging as a formidable player. SeaTown Holdings International, a subsidiary of Temasek, has just closed its second private credit fund, SeaTown Private Credit Fund II (PCF II), ... |
| 29.08.2024 | Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, inc... |
| 06.08.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 04.12.2023 | Latest Updates of Viva's Portfolio Companies | HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 26.09.2023 | Latest Updates of Viva's Portfolio Companies | HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companie... |
Show more